336 related articles for article (PubMed ID: 25360237)
1. Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.
Ai J; Tiu RV
Ther Adv Hematol; 2014 Aug; 5(4):107-20. PubMed ID: 25360237
[TBL] [Abstract][Full Text] [Related]
2. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
3. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
4. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
Elnair R; Galal A
BMC Cancer; 2018 Nov; 18(1):1097. PubMed ID: 30419862
[TBL] [Abstract][Full Text] [Related]
5. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
Tabarestani S; Movafagh A
Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
[TBL] [Abstract][Full Text] [Related]
6. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y
Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711
[TBL] [Abstract][Full Text] [Related]
7. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
Cayuela JM; Chomel JC; Coiteux V; Dulucq S; Escoffre-Barbe M; Etancelin P; Etienne G; Hayette S; Millot F; Nibourel O; Nicolini FE; Réa D;
Bull Cancer; 2020 Jan; 107(1):113-128. PubMed ID: 31353136
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia.
Amarante-Mendes GP; Rana A; Datoguia TS; Hamerschlak N; Brumatti G
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057108
[TBL] [Abstract][Full Text] [Related]
9. Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant
Lu L; Kok CH; Saunders VA; Wang J; McLean JA; Hughes TP; White DL
Oncotarget; 2018 Oct; 9(78):34735-34747. PubMed ID: 30410673
[TBL] [Abstract][Full Text] [Related]
10. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Moore FR; Yang F; Press RD
Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia.
Tiribelli M; Eskazan AE
Oncol Ther; 2019 Dec; 7(2):95-100. PubMed ID: 32699984
[TBL] [Abstract][Full Text] [Related]
13. Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.
Lau A; Seiter K
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):186-96. PubMed ID: 24456839
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
McCarron SL; O'Connor LM; Langabeer SE; Conneally E
Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Terasawa T; Dahabreh I; Trikalinos TA
PLoS Curr; 2010 Dec; 2():RRN1204. PubMed ID: 21188137
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
Soverini S; de Benedittis C; Mancini M; Martinelli G
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S120-8. PubMed ID: 26297264
[TBL] [Abstract][Full Text] [Related]
17. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.
Shih LY; Kuo MC; Kuo CY; Lin TH; Bai LY; Chen TY; Wang MC; Lin TL; Lan YJ; Chen CC; Yang Y; Hsiao PC; Lai CL; Chang CH; Lin TH
Leuk Res; 2013 Jan; 37(1):43-9. PubMed ID: 23062378
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.
Khoury HJ; Bixby DL
Leuk Lymphoma; 2015 Mar; 56(3):568-76. PubMed ID: 24884315
[TBL] [Abstract][Full Text] [Related]
19. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
[TBL] [Abstract][Full Text] [Related]
20. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
